Hemerion, a company specializing in the development of innovative cancer therapies, has been selected as a finalist for the INPI 2024 trophies in the “Partnership Research” category. Created in 1991, this prestigious competition organized by the Institut National de la Propriété Industrielle (INPI) rewards companies with exemplary intellectual property strategies.
This selection rewards the work done by Hemerion since its creation in 2020 to protect and develop the preclinical and clinical research on photodynamic therapies carried out for over 20 years by INSERM, the Lille University Hospital and the University of Lille.
The company’s most advanced technology combines a photosensitizing drug, Pentalafen®, and an illumination platform, Heliance®. It is designed to improve current treatments for glioblastoma, the most common form of brain cancer.
This combination therapy has been in clinical trials since 2018 and is targeted for commercial launch by 2029. It could significantly improve patient survival and quality of life in the face of a highly aggressive pathology.
Hemerion places intellectual property at the heart of its strategy to support its growth. The company has developed unique know-how and fully integrates its innovation approach into its quality policy. Its innovations are systematically protected by patents, designs and trademarks, all of which constitute high value-added intangible assets. This intellectual property strategy anticipates the future and guarantees Hemerion’s long-term ability to innovate, offer new therapeutic solutions and maintain its leadership position.
Hemerion’s selection for the INPI trophies underlines the ability of its teams to translate scientific advances into concrete therapeutic solutions adapted to the needs of caregivers and patients.